Global initiative to demonstrate operational excellence in Nigeria for metastatic colorectal cancer patients
Today, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer. The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries.
The ICM initiative is a collaboration between the Clinton Health Access Initiative (CHAI) and the Parker Institute for Cancer Immunotherapy (PICI), along with Bristol Myers Squibb (BMS) and Roche, working ...